酶联免疫法与电化学发光法检测AFP肿瘤标志物结果对比分析

目的探讨酶联免疫法(ELISA)与电化学发光法(ECLIA)检测血清甲胎蛋白(AFP)肿瘤标志物的检测结果比较。方法采用酶联免疫法和电化学发光法,对2012年1月至2012年6月期间采集的60例血清标本,进行甲胎蛋白的检测,并对两种检测方法的结果,进行比较和分析。结果通过最小二乘法拟合直线方式,比较酶联免疫法(Y)与电化学发光法(X)检测结果,是否具有相关性,结果表明酶联免疫法与电化学发光法具有线性关系,并且具有高度相关性。首先对两种检测方法的甲胎蛋白检测结果,进行正态分布分析,结果显示符合正态分布,然后对均值,进行t检验,结果显示,在95%的可信区间,双尾检验的P=0.2875,表明酶联免疫法与电化学发光法的检测结果不具有统计学意义。结论酶联免疫法与电化学发光法都能较为准确的反应甲胎蛋白水平,对于肿瘤的诊断和治疗的预后,提供重要的理论依据。     

酶联免疫法与电化学发光法检测AFP肿瘤标志物结果的对比分析

目的：探讨酶联免疫法（ELISA）与电化学发光法（ECLIA）检测血清甲胎蛋白（AFP）肿瘤标志物结果对比分析。方法选取2011年1月~2012年12月120例血清标本,分别应用酶联免疫法和电化学发光法进行AFP检测,予以对比。结果应用最小二乘法拟合直线方式,酶联免疫法与电化学发光法存在线性关系,呈现正态分布,95%可信区间内（P〉0.05）,酶联免疫法与电化学发光法的检测结果差异无统计学意义。结论酶联免疫法与电化学发光法均可显示甲胎蛋白水平,在肿瘤诊断治疗中,具有较准确理论价值。     

酶联免疫法与电化学发光法检测AFP肿瘤标志物结果的对比分析

目的探讨酶联免疫法与电化学发光法检测AFP肿瘤标志物结果的对比分析。方法选取本院近年来收治68例肿瘤患者血清标本进行检测,分别采用酶联免疫法及电化学发光法对血清中甲胎蛋白（AFP）水平进行检测。结果两种方法检测血清内游离AFP含量比较差异无统计学意义（P〉0.05）;电化学法与对比酶联免疫法〉0.99,由此可见,与高度有较大关系;在95%可信度下,通过对双样本均值分析的t检验,P〉0.05,由此可见,电化学发光法与对比酶联免疫法比较差异无统计学意义（P〉0.05）。结论在AFP检测中,酶联免疫法与电化学发光法一致性较高,在肿瘤标志物的诊断中具有较高的使用价值。     

酶联免疫法与电化学发光法检测血清甲胎蛋白肿瘤标志物结果的对比分析

目的 对比酶联免疫法（ELISA）与电化学发光法（ECLIA）检测血清甲胎蛋白（AFP）肿瘤标志物的结果。方法 肿瘤科住院患者72例,采集血清标本,分别利用酶联免疫法与电化学发光法对各标本中AFP水平进行检测,对比两组方法所得检测结果。结果 ELISA与ECLIA均可清楚、准确反映血清AFP水平,且两种检测方法相关系数在0.99以上,在95%CI可信区间内,双尾检验P=0.2861,说明ELISA与ECLIA的检测结果差异无统计学意义（P〉0.05）。结论 酶联免疫法与电化学发光法可对血清甲胎蛋白这一肿瘤标志物的水平予以准确反映,且检测结果无显著差异,可为肿瘤诊断与治疗提供重要依据。     

酶联免疫法与电化学发光法检测AFP肿瘤标志物结果的对比分析

目的对比分析酶联免疫法(ELISA)与电化学发光法(ECLIA)检测血清中肿瘤标志物甲胎蛋白(AFP)的结果并评价其应用价值。方法采用酶联免疫法及电化学发光法对176份血清样本进行AFP含量检测,并对两种检测方法的结果进行比较和分析。结果 ELISA法与ECLIA法均能准确的检测出血清中AFP的含量,统计学分析表明两组检测结果呈高度相关性,相关系数>0.99,双样本均值分析t检验下双尾检验P=0.307,表明两组检测结果比较无显著差异,P>0.05,不具有统计学意义。结论酶联免疫法与电化学发光法在检测AFP结果上有较高的一致性,可为临床肿瘤诊断及治疗提供指导。     

分析电化学发光免疫法与酶联免疫吸附试验法检测人类免疫缺陷病毒的临床效果

目的分析电化学发光免疫(ECLIA)法与酶联免疫吸附试验(ELISA)法检测人类免疫缺陷病毒(HIV)的结果。方法 12000份血液样本,均使用电化学发光免疫法以及酶联免疫吸附试验法对HIV感染情况进行检测分析,比较两种检测方式的上机初筛结果、阳性确诊例数以及诊断准确率。结果 12000份样本,经电化学发光免疫法检测初筛阳性30例,经酶联免疫吸附试验法检测初筛阳性35例。两种检测方法初筛阳性率比较差异无统计学意义(χ²=0.386, P=0.535>0.05)。经电化学发光免疫法诊断准确30例,经酶联免疫吸附试验法诊断准确30例,两种检测方法诊断准确率比较差异无统计学意义(χ²=0, P=1>0.05)。12000份样本,经电化学发光免疫法检测,临界值处于150~220的阳性患者最多,共计20例,占比66.67%;经酶联免疫吸附试验法检测,不同吸光值与临界值的比值处于1.35~1.80的阳性患者最多,共计19例,占比63.33%。结论对HIV感染情况进行检测,电化学发光免疫法的准确率、灵敏度更高,在实际检测中的耗时更短,操作难度更小,不管是从临床诊断准确率方面分析,还是从临床工作开展情况来看,均更有益于临床工作效率及质量的提升。     

化学发光法和酶联免疫法检测乙肝病毒血清的效果

目的:探讨化学发光法和酶联免疫法检测乙肝病毒血清的效果。方法:对2018年6月～2018年12月某院413例乙肝病毒筛查病人进行研究分析,采集血液标本,平均分为两份,分别采用化学发光法和酶联免疫法检测乙肝病毒血清,比较检测结果。结果:化学发光法检出乙肝病毒血清阳性189例(45.76%),酶联免疫法检出阳性125例(30.27%),差异具有统计学意义(P0.05);酶联免疫法的中浓度HBsAg含量的批内重复率、批间重复率分别为9.48%、14.92%,显著高于化学发光法1.16%、5.47%;低浓度HBsAg含量的批内重复率、批间重复率分别为12.85%、19.47%,显著高于化学发光法2.42%、7.29%,差异具有统计学意义(P0.05)。两种检测方法高浓度HBsAg含量的批内重复率与批间重复率比较,不具有统计学意义(P0.05)。结论:临床检测乙肝病毒血清,应用化学发光法的准确率比酶联免疫法更高,值得推广。     

酶联免疫法、免疫胶体金法和电化学发光免疫分析法对乙型肝炎血清标志物的检测结果分析

目的探讨酶联免疫法、免疫胶体金法和电化学发光免疫分析法对乙型肝炎血清标志物的检测效果。方法选择我院肝病门诊2014年7月收治的75例就诊者,分别采用酶联免疫法、免疫胶体金法和电化学发光免疫法检测75例就诊者的血清HBsAg、HBeAg、HBeAb、HBcAb、HBsAb水平进行检测,并在B超引导下快速穿刺病理组织,判断75例就诊者病理诊断结果。结果三种检验方法的灵敏度、特异度依次为电化学发光免疫分析法>酶联免疫法>胶体金法,其中电化学发光免疫分析法明显高于胶体金法,P<0.05,其余各组间对比差异无统计学意义,P>0.05。结论电化学发光免疫分析法是乙型肝炎的灵敏度及特异度均较高的诊断方法。     

电化学发光免疫法与酶联免疫法检测乙肝病毒标志物比较研究

目的探讨电化学发光免疫法与酶联免疫法检测乙肝病毒标志物的临床效果。方法选择2016年1月~2017年5月在我院因疑似乙型病毒性肝炎而行乙肝病毒标志物检查的患者200例为研究对象,200例同时采用电化学发光免疫法和采用酶联免疫法进行HBsAg检测,比较两种方法的HBsAg阳性率。取不同浓度HBsAg定值参比血清,用阴性血清进行倍比稀释,同时用两种方法检测,比较两组最低检出浓度。结果电化学发光免疫法HBsAg阳性率显著高于ELISA方法,差异有统计学意义(P<0.05)。不同浓度HBsAg靶值电化学发光免疫法检测的最低浓度显著低于ELISA组,差异有统计学意义(P<0.05)。结论电化学发光免疫法检测乙肝病毒标志物HBsAg比ELISA法阳性率高,最低检出浓度更低,提示灵敏度更高。     

EP9-A2对两种发光免疫分析法的一致性分析

目的对EP9-A2法在微粒子化学发光免疫分析法和电化学发光免疫分析法的一致性研究中的应用情况进行分析探讨。方法抽取在2011年3月至2013年3月间我院收集的血清标本63份,对其采取微粒子化学发光免疫分析法和电化学发光免疫分析法对IgE水平进行检测,而后采取EP9-A2法并对检测结果一致性进行分析。结果微粒子化学发光免疫分析法和电化学发光免疫分析法的检测结果存在显著线性关系,结果偏差在允许范围内。结论 EP9-A2法在微粒子化学发光免疫分析法和电化学发光免疫分析法的一致性研究中具有重要价值,值得关注。     

Serum alpha - fetoprotein levels in patients with cystic fibrosis and their parents and siblings.

Patients with cystic fibrosis (C.F.) showed raised serum levels of alpha-fetoprotein (AFP). A moderate but significant increase in serum AFP was present in their parents and some siblings. There was no correlation between the clinical severity of the disease and serum AFP concentration. Samples from control groups with gluten-induced malabsorption and bronchiectasis had normal levels. Persistent synthesis of AFP may be an associated marker of C.F. genes, and estimation of serum AFP might help in detecting heterozygote carriers in families at risk.     

CMIA、FPIA、MEIA与EMIT测定血药浓度的比较分析

目的：分析比较化学发光微粒子免疫分析法（CMIA）、荧光偏振免疫分析法（FPIA）、微粒子捕捉免疫分析法（MEIA）和酶扩大免疫分析法（EMIT）测定血清丙戊酸（VPA）、全血环孢霉素A（CsA）、血清卡马西平（CBZ）和血清地高辛（DIG）浓度的一致性。方法：通过测定高、中、低浓度质控样品,评价各方法的准确度及精密度,并对临床患者的VPA、CsA、CBZ和DIG样本进行测定,比较4种方法测定结果的相关性。结果：CMIA与EMIT（测定值为函数Y）比较,测定VPA的结果具有良好的相关性和差异性,Y_EMIT=1.172X_CMIA+0.227（r=0.97）,EMIT的测定结果比CMIA平均高17.49%。FPIA与EMIT比较,测定结果具有良好的相关性：VPA,Y_EMIT=1.259X_FPIA-4.671（r=0.97）;CsA,Y_EMIT=0.832X_FPIA+17.63（r=0.97）;CBZ,Y_EMIT=1.156X_FPIA-2.657（r=0.98）;MEIA与EMIT比较,测定结果有相关性：DIG,Y_EMIT=0.634X_MEIA+0.018（r=0.91）;其中CsA的EMIT测定结果比FPIA平均低2.08%,DIG的EMIT测定结果比MEIA平均低35.91%,而VPA的EMIT测定结果比FPIA平均高16.83%、CBZ的EMIT测定结果比FPIA平均高3.07%。结论：CMIA测定VPA血药浓度、FPIA测定VPA、CsA、CBZ及MEIA测定DIG血药浓度与EMIT的测定结果,存在差异性（P<0.05）,临床应用中应予以关注并作相应调整。     

首次应用酶联免疫法检测血浆纤维结合蛋白

目的 探讨血清纤维结合蛋白(Fn)含量的检测方法。方法 首次应用酶联免疫法(ELISA)检测待测血清,测定其光密度(D值),判定待测血清中Fn的含量。结果 该方法线性范围50～300mg/L,批内、日内、日间的CV分别为2.37％、2.89％、3.24％;回收率98.79％。结论 该方法线性范围适宜,准确度、精密度较好,符合临床检验工作要求。     

Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus

It is suggested that specific methods of Tacrolimus monitoring rather than immunoassays which over-estimate Tacrolimus levels, should be used in transplant recipients. There is limited data, however, comparing clinical outcomes of renal transplantation using each of these techniques. In this study, 40 renal transplant recipients with Tacrolimus monitoring by Microparticle Enzyme Immunoassay (MEIA; target trough level 10-15 ng/ml) were compared with 40 patients monitored by High Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS; target trough level 8-13 ng/ml). All received anti CD25 antibody induction and Mycophenolate Mofetil in a steroid sparing protocol. No demographic differences were seen between MEIA and HPLC-MS groups. All patients were followed for 6 months. Patient survival was 100% in both groups; graft survival was 100% in the MEIA group and 97.5% in the HPLC-MS group. The groups did not differ in the number of dose changes required in the first 6 months or in the number of patients displaying Tacrolimus levels within target range at three and six months. Delayed graft function occurred in 14 patients in the MEIA group and 12 patients in the HPLC-MS group (P = NS). Biopsy-proven acute rejection occurred in 4 patients in the MEIA group and 1 patient in the HPLC-MS group (P = 0.17). Biopsy proven acute Tacrolimus nephrotoxicity occurred in 6 patients in the MEIA group, and 7 in the HPLC-MS group (P = NS). No difference was seen in serum creatinine or estimated creatinine clearance at 3 or 6 months. No difference between groups was seen in systolic or diastolic blood pressure, or total cholesterol at 3 or 6 months. 2 patients in the MEIA group developed CMV disease and 1 developed posttransplantation diabetes mellitus. CMV and posttransplantation diabetes were not seen in the HPLC-MS group. 2 patients in each group developed reversible tremor. This study suggests that renal transplantation with HPLC-MS monitoring of Tacrolimus is safe and effective.     

TNF-α/hs-CRP双标记时间分辨荧光免疫法用于脓毒症早期筛查诊断的研究

目的 建立一种双标记时间分辨荧光免疫法（TRFIA）用于定量检测血清中肿瘤坏死因子-α（TNF-α）和超敏C-反应蛋白（hs-CRP）水平。方法 将抗TNF-α和hs-CRP单克隆抗体包被在96孔板,制备铕（Eu³⁺）和钐（Sm³⁺）检测抗体偶联物,建立双抗体夹心TRFIA法并组装成试剂盒,评价此试剂盒的灵敏度、线性范围、加标回收率和各项检测性能。结果 建立了TRFIA检测血清TNF-α和hs-CRP水平的新方法并组装成试剂盒,此试剂盒对TNF-α检测的线性范围为0~100 ng/L,灵敏度为0.05 ng/L,对hs-CRP检测的线性范围为0~100 mg/L,灵敏度为0.02 mg/L;对TNF-α检测的加标回收率92.00%~107.00%,对hs-CRP检测的加标回收率95.00%~106.82%,与其他常见的血清干扰物质无明显的交叉反应;对TNF-α检测的批内CV 4.57%~9.24%,批间CV 5.13%~9.27%;对hs-CRP检测的批内CV 3.57%~7.69%,批间CV 6.07%~10.00%;试剂盒能够在4 ℃稳定保存6个月,37 ℃下可稳定保存7 d以上。TNF-α的检测阈值为0.44 ng/L,hs-CRP的检测阈值为1.41 mg/L。该试剂盒检测判定结果与临床情况相一致,符合率100%。结论 双标记TRFIA法可定量检测TNF-α和hs-CRP水平,具有灵敏度和准确度高、特异性强、方便快捷等优点,可为脓毒症临床样品的早期筛查、疗效评价和预后评估提供一种新的检测方法。     

化学发光法测定甲胎蛋白的临床应用

目的探讨化学发光法测定甲胎蛋白(AFP)的临床应用。方法采用化学发光法测定正常人243例、原发性肝癌患者76例、其它肝病患者165例、非肝癌的癌症患者173例、肝癌术后24例血清中AFP的含量,同时与放射免疫法测定比较。结果以AFP<20ng/ml为正常值,AFP测定的阳性率为:正常人0.8%、原发性肝癌88.1%、其它肝病7.3%、非肝癌的癌症13.87%、肝癌术后41.67%(复发)。与放射免疫法测定比较:相关性R=0.942。结论化学发光法测定AFP结果可靠,能满足临床需要,对于肝癌的诊断和复发有诊断价值。     

CA125、AFP、CEA、CA19-9检测诊断卵巢癌的临床应用价值

目的　探讨糖链抗原 (CA12 5 )、甲胎蛋白 (AFP)、癌胚抗原 (CEA)、糖链抗原 (CA19 9)诊断卵巢癌的价值。方法　采集 2 96例住院患者的血清 ,其中卵巢癌 4 7例 ,卵巢良性病变 2 4 9例 ,用化学发光法检测其血清CA12 5、AFP、CEA、CA19 9值。结果　卵巢癌组患者血清CA12 5的阳性率 (6 3 83% ) ,明显高于良性卵巢病变组(P <0 0 1) ;浆液性卵巢癌CA12 5的阳性率 (88 89% ) ,明显高于黏液性卵巢癌的阳性率 16 6 7% (P <0 0 5 )。早期卵巢癌CA12 5、AFP、CA19 9、CEA联合检测阳性率较CA12 5单项检测的阳性率明显升高 (P <0 0 5 ) ;卵巢癌第一次手术切除瘤体 <10cm组与 >10cm组的CA12 5检测值差异无显著性 (P >0 0 5 )。结论　CA12 5在临床诊断卵巢癌中具有重要价值 ,尤以诊断浆液性卵巢癌为突出 ;CA12 5、AFP、CA19 9、CEA联合检测有助于提高早期卵巢癌的检出率 ;CA12 5检测值与卵巢癌第一次手术切除瘤体的大小无关。     

Use of sample hematocrit value to correct blood tacrolimus concentration derived by microparticle enzyme immunoassay

The quality of microparticle enzyme immunoassay (MEIA) for blood tacrolimus is guaranteed in samples with hematocrit (Ht) values of 25 to 45%. Because MEIA provides inaccurate blood tacrolimus concentrations in samples with Ht out of this range (i.e. <25% or >45%), correction of the calibration is required for therapeutic drug monitoring. The authors demonstrated previously that overestimated MEIA tacrolimus concentration could be corrected by modified, calibrated MEIA (cMEIA) using the original calibrator. Here, an equation was established to more easily derive a corrected tacrolimus concentration by calculation (MEIAcalc) using the Ht of each sample. The tacrolimus concentrations of 99 whole-blood samples with low Ht (<25%) were then tested by the 3 assay methods: MEIA, cMEIA, and MEIAcalc. MEIA gave a significantly higher blood concentration of tacrolimus (median 12.9 ng/ml, range 3.6-26.4 ng/ml) than did cMEIA (median 10.0 ng/ml, range 0.2-21.1 ng/ml, p<0.05). This overestimation was eliminated by using MEIAcalc. There was no difference in blood tacrolimus concentration between cMEIA and MEIAcalc (median 10.0 ng/ml, range 1.7-21.4 ng/ml). MEIAcalc can be used to correct the tacrolimus concentration in samples obtained from patients with unstable Ht values.     

Rapid determination of serum melatonin by ESI-MS-MS with direct sample injection

This paper describes a rapid, simple and sensitive analytical method for the quantitative determination of melatonin in human serum by ESI-MS-MS with direct serum sample injection and on-line extraction. The method uses N-acetyltryptamine as the internal standard. It has high specificity and sensitivity for serum melatonin analysis. The internal calibration curve shows a wide linear range from 0.500 to 200 ng/ml with a correlation coefficient, R(2) > 0.999. The limit of quantitation is 0.500 ng/ml and the limit of detection is 0.100 ng/ml with 10-microl sample injection. The recoveries of serum melatonin at three levels are approximately 70%. The intra-assay precision (n = 5) is between 0.8 and 2.0% and the inter-assay precision (n = 3) is between 1.5 and 5.9% over the calibration range. This method has a total analysis time of less than 9 min. It can be used for the measurement of melatonin in human blood.     

全自动生化仪免疫比浊法检测血清白蛋白的方法学评价

目的使用免疫比浊法对血清白蛋白（ALB）测定的方法学进行评价。方法根据美国临床实验室标准化委员会（NCCLS）的标准,对免疫比浊法测定血清白蛋白的精密度、线性范围、回收率及准确性等指标进行测试．同时与溴甲酚绿法进行相关性的比较。结果精密度批内CV〈4．0,批间CV〈5．0。ALB线性范围可达5-89g／L,平均回收率为102.3％;抗干扰性强,当Hb≤50g／L,胆红素≤400μmol／L,TG≤23．0mmol／L时对测定无影响：与溴甲酚绿法对比,直线回归方程Y=1．05X＋5．56（Y：免疫比浊法：X：溴甲酚绿法）,相关系数r=0．926,提示两种方法有良好的相关性。结论免疫比浊法检测血清白蛋白是较为理想的新方法,完全能满足临床需要。